TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:16
Adaptimmune Therapeutics PLC ( ADAP ) https://www.adaptimmune.com
0.57USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-17.74%
ADAP
SPY
32.66%
-85.02%
ADAP
SPY
108.59%
-58.86%
ADAP
SPY
302.52%
ADAP
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
902.35
794.93
4.66
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-20.08
5.16
11.28
-3.83
0.00
617.66
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-35.89
100.00
0.60
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
14.3296
-6.66
-4.18
2.72
Other Earnings and Cash Flow Stats:
Adaptimmune Therapeutics PLC ( ADAP ) Net Income TTM ($MM) is -44.93
Adaptimmune Therapeutics PLC ( ADAP ) Operating Income TTM ($MM) is -49.26
Adaptimmune Therapeutics PLC ( ADAP ) Owners' Earnings Annual ($MM) is 0.00
Adaptimmune Therapeutics PLC ( ADAP ) Current Price to Owners' Earnings ratio is 0.00
Adaptimmune Therapeutics PLC ( ADAP ) EBITDA TTM ($MM) is -38.00
Adaptimmune Therapeutics PLC ( ADAP ) EBITDA Margin is 0.60%
Capital Allocation:
Adaptimmune Therapeutics PLC ( ADAP ) has paid 0.00 dividends per share and bought back -1308.305701 million shares in the past 12 months
Adaptimmune Therapeutics PLC ( ADAP ) has increased its debt by 53.069 million USD in the last 12 months
Capital Structure:
Adaptimmune Therapeutics PLC ( ADAP ) Interest-bearing Debt ($MM) as of last quarter is 78
Adaptimmune Therapeutics PLC ( ADAP ) Annual Working Capital Investments ($MM) are -33
Adaptimmune Therapeutics PLC ( ADAP ) Book Value ($MM) as of last quarter is 79
Adaptimmune Therapeutics PLC ( ADAP ) Debt/Capital as of last quarter is 98%
Other Balance Sheet Stats:
Adaptimmune Therapeutics PLC ( ADAP ) has 116 million in cash on hand as of last quarter
Adaptimmune Therapeutics PLC ( ADAP ) has 63 million of liabilities due within 12 months, and long term debt 49 as of last quarter
Adaptimmune Therapeutics PLC ( ADAP ) has 1534 common shares outstanding as of last quarter
Adaptimmune Therapeutics PLC ( ADAP ) has 0 million USD of preferred stock value
Academic Scores:
Adaptimmune Therapeutics PLC ( ADAP ) Altman Z-Score is -0.96 as of last quarter
Adaptimmune Therapeutics PLC ( ADAP ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Adaptimmune Therapeutics PLC ( ADAP ) largest shareholder is owning shares at 0.00 ($MM) value
Piccina Cintia(an insider) Sold 24531 shares of Adaptimmune Therapeutics PLC ( ADAP ) for the amount of $22813.83 on 2024-06-18
0.38% of Adaptimmune Therapeutics PLC ( ADAP ) is held by insiders, and 60.27% is held by institutions
Adaptimmune Therapeutics PLC ( ADAP ) went public on 2015-05-06
Other Adaptimmune Therapeutics PLC ( ADAP ) financial metrics:
FCF:-55.80
Unlevered Free Cash Flow:0.00
EPS:-0.05
Operating Margin:-35.89
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-88.10
Beta:2.72
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Adaptimmune Therapeutics PLC ( ADAP ) :
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.